Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Ratios

Gain Therapeutics (GANX) Shares Issued (2021 - 2025)

Gain Therapeutics has reported Shares Issued over the past 4 years, most recently at $3.2 million for Q4 2025.

Quarterly results put Shares Issued at $3.2 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $8.4 million (up 14418.56% YoY), and the annual figure for FY2025 was $3.2 million, up 5477.02%.
Shares Issued for Q4 2025 was $3.2 million at Gain Therapeutics, up from $42000.0 in the prior quarter.
Over the last five years, Shares Issued for GANX hit a ceiling of $42.6 million in Q1 2021 and a floor of -$56089.0 in Q3 2024.
Median Shares Issued over the past 4 years was $761643.5 (2023), compared with a mean of $4.6 million.
Biggest five-year swings in Shares Issued: tumbled 135.7% in 2024 and later soared 19568.51% in 2025.
Gain Therapeutics' Shares Issued stood at $42.6 million in 2021, then plummeted by 98.23% to $752767.0 in 2023, then plummeted by 107.45% to -$56089.0 in 2024, then soared by 5763.87% to $3.2 million in 2025.
The last three reported values for Shares Issued were $3.2 million (Q4 2025), $42000.0 (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.